Results 21 to 30 of about 124,349,391 (271)

Clinical validation of the novel CLIA-CA-62 assay efficacy for early-stage breast cancer detection

Frontiers in Oncology, 2023
BackgroundWithout organized screening programs up to 60-70% of breast cancers are diagnosed at advanced stages that have significantly lower five-year survival rate and poorer outcomes, which is a serious global public health problem.
Marina Sekacheva, Alexander Boroda, Anastasia Fatyanova, Alexander Rozhkov, Nikolai Bagmet   +4 more
doaj   +1 more source

Investigation of a Stable Interaction of Levothyroxine with AFP Through Molecular Modelling

Cumhuriyet Science Journal
Thyroid dysfunctions are common all over the world, and accordingly, the use of thyroid drugs has increased. Incorrect measurement of tumor markers may lead to missed cases of cancer.
Emel Akbaba, Deniz Karataş, Ataman Gönel, Ezgi Soylu, Beste Kiraz, Yusur Ammar Almahdi   +5 more
doaj   +1 more source

Tissue ELISA and Serum Amperometric Magnetoimmunosensor of ECD-HER2 In Stratifying Subtyping of Egyptian Woman Breast Cancers [PDF]

Zagazig University Medical Journal
Background: Detection of HER2 extracellular domain (ECD) amperometric magnetoimmunosensor (AM) investigated on raw cell lysates, intact breast cancer cells, and commercial and healthy sera except on patients' samples.
Sameh Nakhla, Zynab Elwafe, Ahmed Saad Saad, Tarek Aref, Noha Ragab, inas elbadry, Unai Eletxigerra Eletxigerra, Susana Campuzano, Jesus Martínez-Perdiguero, Santos Merino Merino, José M. Pingarrón, Salah Abdelmoneim, Eman El-Abd   +12 more
doaj   +1 more source

Tumor Markers in Dogs with Mammary Gland Tumors

Acta Veterinaria, 2023
The aim of this study was to determine and compare values of carcinoembryonic antigen (CEA) and cancer antigen (CA 15-3) in 50 bitches with mammary tumors and 150 clinically healthy dogs.
Valencakova Alexandra, Kiselova-Bilekova Beata, Figurova Maria, Hornak Slavomir, Hornakova Lubica   +4 more
doaj   +1 more source

Clinical evaluation comparing AxSYM CA 15-3, IMx CA 15-3 and Truquant BRTM RIA.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 1999
A retrospective clinical study was conducted to compare results obtained by AxSYM(R) CA 15-3(TM), IMx(R) CA 15-3 and Truquant(R) BRTM RIA using surplus serum specimens from healthy volunteers and patients with benign and malignant diseases. Linear regression analysis of AxSYM and IMx CA 15-3 versus Truquant BR RIA for specimens with results 0-250 U/ml ...
D M, Lynch, P E, Rogers, J C, Love, M J, Salkas, K A, Skarphol, M E, Gross, M G, Lu, V H, Petrides, D J, Bruzek, J L, Cox, K A, Jones, C A, Kelley, D W, Chan   +12 more
openaire   +2 more sources

Multicenter evaluation of the Abbott IMx CA 15-3 assay [PDF]

Clinical Chemistry, 1996
Abstract We describe a new fully automated procedure for the quantitative measurement of CA 15-3: the microparticle enzyme immunoassay (MEIA) technology developed by Abbott Labs. for the IMx automated immunoassay analyzer. The new IMx CA 15-3 test uses two mouse monoclonal antibodies, 115D8 and DF3.
G J, van Kamp, G G, Bon, R A, Verstraeten, D, Lynch, M, Krikau, J, Flückiger, A, Ruibal, P, Kenemans   +7 more
openaire   +2 more sources

sj-docx-1-jbm-10.1177_03936155231158661 - Supplemental material for Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: Diagnostic cancer biomarkers

, 2023
Supplemental material, sj-docx-1-jbm-10.1177_03936155231158661 for Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: Diagnostic cancer biomarkers by Farzaneh Fazli Khalaf, Mehrnaz Asadi Gharabaghi ...
Farzaneh Fazli Khalaf (14821455), Hamidreza Davari (14821461), Maryam Balibegloo (13113532), Mehrnaz Asadi Gharabaghi (14821458), Samaneh Afshar (14821464), Behnaz Jahanbin (14821467)   +5 more
core   +1 more source

Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients

BMC Cancer, 2012
Background Mucin-1 is known to be over-expressed by various human carcinomas and is shed into the circulation where it can be detected in patient’s serum by specific anti-Mucin-1 antibodies, such as the tumour marker assays CA 15–3 and CA 27.29.
Engelstaedter Verena, Heublein Sabine, Schumacher Anamur Lan, Lenhard Miriam, Engelstaedter Helen, Andergassen Ulrich, Guenthner-Biller Margit, Kuhn Christina, Rack Brigitte, Kupka Markus, Mayr Doris, Jeschke Udo   +11 more
doaj   +1 more source

Gene expression of Epithelial Membrane Protein 2 gene and β1-Integrin gene in patients with breast cancer

Biochemistry and Biophysics Reports, 2020
Background: Breast cancer is the most common invasive cancer and the leading cause of cancer death in women. The function of over a thousand genes is reported as affected by genetic modifications in breast cancer. Objectives: To study the gene expression
Samah EL-Ghlban, Elsayed Saber AbouElnour, Abd El-Monem Abd El- Kader EL- Torgoman, Saeed Mohamed Saeed Abu Elabas   +3 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source